GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
GOSSAMER BIO, INC. (GOSS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $1.06 per share as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $1.06.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $1.11.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $2.48.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $2.52.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $1.06 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.11 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.48 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.52 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.60 10-Q · filed 2025-08-05 |
| 2025-03-31 | $2.78 10-Q · filed 2025-05-15 |
| 2024-12-31 | $3.20 10-K · filed 2025-03-13 |
| 2024-09-30 | $3.55 10-Q · filed 2024-11-07 |
| 2024-06-30 | $3.64 10-Q · filed 2024-08-12 |
| 2024-03-31 | $3.80 10-Q · filed 2024-05-07 |
| 2023-12-31 | $4.17 10-K · filed 2024-03-05 |
| 2023-09-30 | $4.72 10-Q · filed 2023-11-09 |
| 2023-06-30 | $5.83 10-Q · filed 2023-08-08 |
| 2023-03-31 | $12.19 10-Q · filed 2023-05-09 |
| 2022-12-31 | $12.19 10-K · filed 2023-03-17 |
| 2022-09-30 | $12.17 10-Q · filed 2022-11-03 |
| 2022-06-30 | $12.01 10-Q · filed 2022-08-09 |
| 2022-03-31 | $12.40 10-Q · filed 2022-05-10 |
| 2021-12-31 | $12.63 10-K · filed 2022-03-03 |
| 2021-09-30 | $12.74 10-Q · filed 2021-11-08 |
| 2021-06-30 | $12.89 10-Q · filed 2021-08-09 |
| 2021-03-31 | $12.76 10-Q · filed 2021-05-06 |
| 2020-12-31 | $12.66 10-K · filed 2021-02-26 |
| 2020-09-30 | $12.57 10-Q · filed 2020-11-10 |
| 2020-06-30 | $12.31 10-Q · filed 2020-08-11 |
| 2020-03-31 | $11.38 10-Q · filed 2020-05-12 |
| 2019-12-31 | $7.25 10-K · filed 2020-03-24 |
| 2019-09-30 | $3.88 10-Q · filed 2019-11-12 |
| 2019-06-30 | $3.03 10-Q · filed 2019-08-08 |
| 2019-03-31 | $3.20 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |